News

Despite trade war, US drug companies turn to China for key cancer treatments
US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...
Market Inference3h
Arvinas Submits NDA for Breast Cancer Drug
The VeriTac-2 trial assessed vepdegestrant (ARV-471) as a monotherapy compared to fulvestrant in patients with ER+/HER2* ...
Was Jim Cramer Right About Pfizer Inc. (PFE)?
We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...
BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?
BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure ...
Arvinas, Pfizer Seek FDA Approval of Vepdegestrant in Breast Cancer
Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations.
Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment
Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...